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Prostaglandin Hydroperoxidase Catalyzed
Activation of Certain N-Substituted Aryl
Renal and Bladder Carcinogens
by T. V. Zenser,*t S. M. Cohen,t M. B. Mattammal,*t
R. W. Wise, N. S. Rapp* and B. B. Davis*t
Certain carcinogens are thought to induce renal and bladder cancer following metabolic activa-
tion. We propose a model system for this activation and provide supporting experimental evidence.
This model proposes that renal and bladder carcinogens' entry into the urinary tract is facilitated,
that carcinogens are activated by the prostaglandin hydroperoxidase activity of prostaglandin en-
doperoxide synthetase (PES), and that activation results in covalent binding to nucleic acids which
can initiate carcinogenesis. Benzidine and the 5-nitrofuran HMN were shown to inhibit uptake of or-
ganic anions and cations, respectively. Carcinogen binding to DNA was dependent upon specific un-
saturated fatty acid substrates and prevented by specific inhibitors of PES, i.e., aspirin. Activation
with organic peroxides or H202 was inhibited by antioxidants but not aspirin. Horseradish peroxi-
dase (HRP) metabolized benzidine but not ANFT. Acetaminophen and the 5-nitrofurans ANFT and
HMN prevented PES '4C-benzidine metabolism. However, only acetaminophen inhibited HRP metab-
olism of benzidine. The only aerobic metabolism we have observed of 5-nitrofurans is PES-catalyzed.
Aspirin (0.5% in the diet) inhibited rat bladder hyperplastic lesions induced by feeding 0.1% or
0.2% FANFT for 6 or 12 weeks. Aspirin reduced bladder prostaglandin synthesis and PES metabo-
lism of FANFT. After one year of an ongoing long-term study, gross examination reveals bladder tu-
mors in 85% of the rats fed 0.2% FANFT and in only 37% of the rats fed FANFT plus 0.5% aspirin.
Introduction
We have developed an experimental model to ex-
plain the initiation by certain chemicals of renal and
bladder cancer. This model is based on the hypothe-
sis that these urinary tract carcinogens are acti-
vated by the hydroperoxidase activity of prosta-
glandin endoperoxide synthetase (PES). Activation
results in initiation of the carcinogenic process. We
have used the 5-nitrofuran carcinogens 2-amino-4-(5
nitro-2-furyl-thiazole (ANFT) and N-[445-nitro-2-
furyl-2-thiazolyl] formamide (FANFT) and the aro-
matic amine benzidine to develop this model. In par-
ticular, advantage was taken of a well-defined rat
model in which urinary bladder cancer is induced
with FANFT (1). We will present the experimental
evidence which supports our model and examine
the possible involvement of other peroxidases in the
initiation of urinary tract carcinogenesis.
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Characteristics of Prostaglandin
Endoperoxide Synthetase
Purified PES enzyme (Fig. 1) has been shown to
consist of two separate activities: fatty acid cyclo-
oxygenase and prostaglandin hydroperoxidase (2).
Fatty acid cyclooxygenase is responsible for the ini-
tial bisdioxygenation of the unsaturated fatty acid.
For arachidonic acid, this product is prostaglandin
G,, a 15-hydroperoxy prostaglandin cyclic endoper-
oxide. The hydroperoxidase activity is responsible
for cleavage of the 15-hydroperoxy group. With
prostaglandin G2 as substrate, the product is the 15-
hydroxy cyclic endoperoxide prostaglandin H2. Pros-
taglandin H2 is the common substrate for synthesis
of prostaglandins and thromboxanes. PES has been
shown to exist as a dimer with each individual sub-
unit having a molecular weight of 72,000 (3).
Certain characteristics of the cyclooxygenase and
hydroperoxidase activities of PES allow separate
examination of each activity. Aspirin has been
shown to irreversibly inhibit fatty acid cyclooxygen-
ase by acetylation of a serine moiety (3). Other non-
steroidal anti-inflammatory drugs, in addition to as-ZENSER ETAL.
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FIGURE 1. Reactions catalyzed by prostaglandin endoperox-
ide synthetase.
pirin, inhibit fatty acid cyclooxygenase. The sub-
strate requirements of fatty acid cyclooxygenase
are very specific. All unsaturated fatty acid sub-
strates have in common the location of a triene sys-
tem which terminates at the sixth carbon from the
alkyl terminus (4). Arachidonic acid is thought to be
the major in vivo substrate. The fatty acid cyclooxy-
genase reaction requires molecular oxygen (5) and
heme (6). By contrast, prostaglandin hydroperoxi-
dase is not inhibited by nonsteroidal anti-inflamma-
tory drugs and will utilize a broad range of sub-
strates. The hydroperoxidase enzyme can only use
ferric heme, while cyclooxygenase can use either
Fe3+-heme or Mn2+-Fe3+-heme (6). PES has been
shown to be uniquely distributed within the kidney
(7) with the most activity in the renal medulla (8).
Immunohistofluorescence studies which localize
PES subcellularly have demonstrated that the en-
zyme system is associated with the endoplasmic re-
ticulum and nuclear membrane (9).
The hydroperoxidase activity of PES is responsi-
ble for the cooxidative metabolism of carcinogens.
Cooxidative metabolism has been demonstrated
with microsomes, intact tissue slices and in vivo.
Major classes of compounds metabolized by PES in-
clude aromatic amines (10), aromatic amides (11), 5-
nitrofurans (10), and polycyclic aromatic hydrocar-
bons (12). Cooxidative metabolism of 7,8-dihydroxy-
7,8- dihydrobenzo(a)pyrene (12) and the aromatic
amines benzidine and 2-naphthylamine (13) has been
shown to result in the formation of mutagens.
Metabolism and Activation of
Benzidine and 5*Nitrofurans by
Microsomal Prostaglandin
Endoperoxide Synthetase
Benzidine and the 5-nitrofuran urinary tract car-
cinogens are not thought to be proximal carcino-
gens because they initiate carcinogenesis at a site
distant from their entry into the body. Therefore,
these carcinogens require activation to elicit their
carcinogenic effects. Using '4C-ANFT and bladder
epithelial microsomes (14), PES-catalyzed activation
was assessed by covalent binding to protein and
DNA (Table 1). Binding determined in the absence
of arachidonic acid was not different from binding in
the absence of microsomes. Addition of arachidonic
acid caused a large increase in ANFT metabolism.
Indomethacin completely inhibited arachidonic acid-
dependent binding. There was no measurable bind-
ing when DNA was added at the end of the stan-
dard incubation for an additional 5 min (not shown).
This suggests that a short-lived reactive interme-
diate of ANFT is formed during the reaction. 15-Hy-
droperoxy-5,8,11,13-eicosatetraenoic acid (15-
HPETE)mediated metabolism is consistent with
the prostaglandin hydroperoxidase component of
PES catalyzing activation of ANFT. 15-HPETE-me-
diated metabolism was not prevented by indometh-
acin but was prevented by the antioxidant vitamin
E. Previous studies have examined mixed-function
oxidase-catalyzed metabolism of ANFT in renal cor-
tex and of FANFT in renal cortex and bladder tran-
sitional epithelial tissue. There was no measurable
mixed-function oxidase-dependent binding in any of
Table 1. Covalent binding of ['4C]ANFT to protein and DNA
catalyzed by prostaglandin endoperoxide synthetase prepared
from rabbit bladder transitional epithelial microsomes.
Binding, nmole/mg protein/5 min
Aqueous, TCA
Conditions precipitable DNA bound
Complete systema 0.16 ± 0.02 0.014 ± 0.002
- Arachidonic acid N.D.b N.D.
- Microsomes 0.002 ± 0.002 0.003 ± 0.002
+ Indomethacin (50pM) N.D. N.D.
15-HPETE (301M) 0.23 ± 0.02 0.026 ± 0.003
+ Indomethacin (100 M) 0.23 ± 0.004 0.024 ± 0.005
+ Vitamin E (50 IAM) N.D. N.D.
aThe complete system consists of 0.5 mg rabbit bladder
transitional epithelial microsomes, 0.024 mM ['4C]ANFT,
0.0012 mM methemoglobin, 0.06 mM arachidonic acid, and the
indicated concentration of test agents in a total volume of 0.25
mL. Where indicated, 15-HPETE was used instead of
arachidonic acid. All inhibitors were preincubated for 2 min at
250C. Data are expressed by mean ± S.E. (n = 3 to 8) (14).
bNot detected.
COOH
5,8,1 1,14 - Eicosatetraenoic acid
Fatty acid 41
cyclo oxygenase _
O0r
N .7 -NCOOH
60H OOH
I P(, hydlroxpro,udase
34ACTIVATION OFN-SUBSTITUTED ARYL CARCINOGENS
those tissues. The only aerobic metabolism of
ANFT or FANFT observed in these tissues is PES
catalyzed. Prostaglandin hydroperoxidase-catalyzed
binding of '4C-benzidine to protein and DNA has
also been reported (15). These results are consistent
with PES playing a role in 5-nitrofuran and benzi-
dine-induced renal and bladder carcinogenesis.
The dose-response effect of indomethacin on renal
inner medullary microsomal synthesis of PGE2 and
cooxidation of '4C-benzidine was used to assess the
relationship between renal prostaglandin synthesis
and cooxidation (Fig. 2). Two separate incubation
conditions were used to assess these effects (16).
One incubation contained 30 j.AM '4C-benzidine and 25
IM unlabeled arachidonic acid. The other contained
25 *M 14C-arachidonic acid and 30 AM unlabeled
benzidine. Cooxidation was assessed as '4C-benzidine
bound to TCA precipitable material and
prostaglandin synthesis as '4C-prostaglandin E2
isolated by thin-layer chromatography. The
similarity in the indomethacin IDso values is con-
sistent with PES-catalyzed prostaglandin E2 syn-
thesis and covalent binding of benzidine to protein.
The benzidine analogs 3,3'-dimethylbenzidine (o-
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FIGURE 2. Effect of indomethacin on PGE2 synthesis and ben-
zidine metabolism. Reaction mixtures contained 0.14 mg of
microsomal protein, 0.1 M phosphate buffer (pH 7.8), 0.025
mM arachidonic acid and 0.03 mM benzidine in a final
volume of 0.1 mL. Microsomes and reaction mixture were
preincubated for 2 min at room temperature before a 10-
min incubation at 37°C. For determination of PGE2 syn-
thesis, ['4C]-arachidonic acid was used. For determination
of benzidine metabolism, ['4C]benzidine was used. The
rates of PGE2 synthesis and total benzidine metabolism
(both TCA-precipitable and non-TCA-precipitable aqueous
fractions) were 0.64 and 0.15 nmole/mg/min, respectively.
These rates each correspond to 100% of their respective
control activity. Values represent the mean of four
determinations (16).
tolidine) and 3',3'-dimethoxybenzidine (o-dianisidine)
are also thought to be carcinogenic (17). We have in-
vestigated the metabolism of these compounds by
PES. Each compound exhibited spectral changes
consistent with metabolism by PES. The spectral
changes catalyzed by horseradish peroxidase and
PES were similar. These results are consistent with
the prostaglandin hydroperoxidase component of
PES catalyzing the metabolism of a variety of aro-
matic amines.
Demonstration of Intact Tissue
Metabolism of 14C-Benzidine by
Prostaglandin Endoperoxide
Synthetase
If PES-catalyzed metabolism of urinary tract car-
cinogens is an important step in initiation of the car-
cinogenic process, this metabolism should be demon-
strable with intact tissue. 14C-Benzidine metabolism
by renal medullary tissue slices was used as a test
system (Fig. 3). Slices were subjected to two succes-
sive incubations with Krebs-Ringer bicarbonate buf-
fer containing 1 mg/mL each of glucose and BSA
(18). Both 0.15 mM arachidonic acid and 25 ,.M 14C-
benzidine were present in only the final incubation.
Other test agents were present in both incubations.
Metabolism was assessed by binding to TCA-precip-
itable material. Benzidine metabolism was indicated
by an increase in radioactivity over the blank which
contained heated tissue slices or slices incubated
anaerobically. 14C-Benzidine binding was increased
by arachidonic acid. While inhibitors of PES pre-
vented this increase, SKF-525A and metyrapone,
inhibitors of mixed-function oxidases, were not
effective. These results are consistent with an ex-
periment demonstrating in vivo PES-catalyzed me-
tabolism of "4C-benzidine by dog kidney (19). 14C- Ben-
zidine was administered by retrograde perfusions
into the renal pelvis through a ureteral catheter.
Benzidine metabolism in subsequent urinary collec-
tions was prevented by meclofenamic acid. These
results are consistent with microsomal, intact tissue
and in vivo metabolism of urinary tract carcinogens
by PES.
Role of Peroxidases in Chemical
Carcinogenesis
Hemeprotein peroxidases are present in mamma-
lian tissues and catalyze metabolic activation of car-
cinogens. Both Forrester (20) and Bartsch (21) dem-
onstrated the conversion of N-hydroxy-2-acetyl-a-
minofluorene to 2-nitrosofluorene and N-acetyl-
aminofluorene. Later Bartsch demonstrated that
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FIGURE 3. Effect of different agents on ['4C]benzidine binding to renal medullary slices. Both 0.15 mM arachidonic acid and 0.025
mM ['4C]benzidine were present only during the second incubation. * No arachidonic acid, 090.15 mM arachidonic acid. Other
test agents were present during both incubations. ['4C]Benzidine binding to TCA precipitable material was determined. Values
are mean ± S.E. of three or more determinations. The asterisk denotes p<0.05 compared to 0.15 mM arachidonic acid alone
(18).
not only horseradish peroxidase but also the mam-
malian enzymes myeloperoxidase and lactoperoxi-
dase catalyzed this reaction (22). In the uterus, di-
ethylstilbestrol is thought to be metabolized to its
ultimate carcinogen by peroxidase (23). We have
demonstrated PES-catalyzed activation of diethyl-
stilbestrol (10). However, two distinct peroxidases
have been reported in uterine tissue (24) and the re-
lationship of these peroxidases to PES is not
known. Differences in substrate specificity (25) and
in the products formed (26) by peroxidases have
been reported. A better understanding of the speci-
ficity of peroxidase-catalyzed activation of urinary
tract carcinogens would improve interpretations of
intact tissue and whole animal experiments and pro-
vide a stronger basis for current experimental
models.
Comparison of Effects of
Prostaglandin Endoperoxide
Synthetase and Horseradish
Peroxidase on 5-Nitrofuran and
Aromatic Amine Metabolism
The catalysis of 14C-benzidine and 14C-ANFT bind-
ing to TCA-precipitable material was examined
with ram seminal vesicle PES and horseradish per-
oxidase. Binding was indicated by an increase in ra-
dioactivity over blank values obtained with samples
containing 2 mg/mL bovine serum albumin but not
enzyme. Both PES and horseradish peroxidase me-
tabolized benzidine (Table 2). Arachidonic acid-but
not HPETE-mediated metabolism-was prevented
by aspirin. The lack of effect of salicylate, the deace-
tylated metabolite of aspirin, suggests that aspirin
inhibition is due to acetylation of the fatty acid cy-
clooxygenase component of PES. At 0.2 mM KCN,
horseradish peroxidase but not PES-catalyzed me-
tabolism was inhibited. The antioxidant vitamin E
prevented binding of "4C-benzidine catalyzed by
both peroxidases. Both peroxidases catalyze binding
of benzidine to DNA as well as protein (not shown).
To further assess the specificity of the peroxidase
enzymes, metabolism of ANFT was determined
(Table 3). PES catalyzed binding of ANFT but
horseradish peroxidase did not. As previously
shown, ANFT binding was consistent with metabo-
lism by prostaglandin hydroperoxidase component
of PES. PES-catalyzed binding of 14C-ANFT to DNA
has been demonstrated (Table 1).
The mechanism of benzidine metabolism by
horseradish peroxidase and prostaglandin endoper-
oxide synthetase was further investigated using
electron paramagnetic resonance. As shown in
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Table 2. Peroxidase-catalyzed binding of '4C-benzidine
to TCA precipitable material.a
Binding, nmole/mg protein/min
Prostaglandin Horseradish
endoperoxide peroxidase
synthetase (x 10-3);b
substrate
Arachidonate HPETE H202,
Inhibitors 0.13 mM 0.05 mM 0.3 mM
None 26.9 ± 3.4 29.3 ± 3.5 38.5 ± 3.5
Cyanide (0.2 mM) 27.2 ± 3.1 30.1 ± 2.4 10.4 ± 0.4
Aspirin (1.2 mM) 1.1 ± 0.2 30.1 ± 1.2 44.7 ± 4.5
Salicylate (2 mM) 21.8 ± 2.1 26.8 ± 1.3
Vitamin E (0.05mM) 14.8 ± 1.8 18.1 ± 0.32 17.9 ± 0.9
aComplete reaction mixture contained solubilized seminal
vesicle microsomes or horseradish peroxidase, 2 mg/mL
bovine albumin, 0.06 mM '4C-benzidine, substrate and
inhibitors as indicated in a final volume of 0.25 mL and were
incubated at 37°C for 3 min. Reactions were stopped and
extracted with ethyl acetate before addition of 0.6 M TCA.
Data expressed as mean ± S.D. (n = 3).
bActual value is obtained by multiplying by 103.
HRP + H202
lOG
+ BENZIDINE
Table 3. Peroxidase-catalyzed binding of '4C-ANFT
to TCA precipitable material.a
Binding, nmole/mg protein/min
Prostaglandin
endoperoxide
synthetase
Horseradish
peroxidase
substrate
Arachidonate HPETE H202,
Inhibitors 0.13 mM 0.05 mM 0.3 mM
None 5.7 ± 0.4 5.6 ± 0.6 N.D.
Cyanide (0.2 mM) 5.3 + 0.4 6.3 ± 1.3 -
Aspirin (12 mM) N.D. 5.9 ± 1.1 -
Salicylate (2 mM) 4.7 ± 0.8 5.1 + 0.9 -
Vitamin E (0.05 mM) 2.3 ± 0.6 2.0 + 0.2 -
aComplete reaction mixture and recovery of TCA
precipitable material was the same as described in Table 2
but with 0.02 mM '4C-ANFT as label. Data expressed as mean
+ S.D.(n = 3).
Figure 4, a benzidine radical was observed with
horseradish peroxidase and H202. This radical was
dependent on the presence of both H202 and horse-
radish peroxidase. Acetaminophen at 200 MM com-
pletely inhibited radical formation by 200 WM benzi-
dine. However, 200 WM ANFT had no effect. This
free radical mechanism of benzidine metabolism
was also observed with prostaglandin endoperoxide
synthetase and arachidonic acid (Fig. 5). Radical for-
mation was prevented by addition of indomethacin.
Both horseradish peroxidase and prostaglandin en-
doperoxide synthetase appear to metabolize benzi-
dine by a similar mechanism. Our results are consis-
tent with recent reports (27, 28) demonstrating
3,5,3',5'-tetramethylbenzidine radical formation with
horseradish peroxidase and prostaglandin hydroper-
oxidase.
- 11202
BOILED
FIGURE 4. Radical formed at room temperature with 100
ng/mL HRP, 100 WM H202 and 200 jM benzidine in 0.1 M
acetate buffer pH 5.0. Measurements were performed over
a 400 G scan range in region around g = 2 with a
modulation amplitude of 10, a modulation frequency of 100
kHz and a microwave power of 20 mW. The instrument
was a Varian E-109E EPR spectrometer.
A model describing the relationship of PES and
other peroxidases in the activation of carcinogens is
illustrated in Figure 6. This model is consistent with
the results above. Three types of peroxidatic reac-
tions are envisioned. Type 1 reactions occur with
carcinogens that are metabolized only by the hydro-
peroxidase component of PES. PES-catalyzed acti-
vation of 5-nitrofurans is a type 1 reaction. Type 2
reactions occur with carcinogens that are metabo-
lized by both prostaglandin hydroperoxidase and
other peroxidases. Aromatic amines and diethylstil-
bestrol activation appears to occur by a type 2 reac-
tion. In contrast to the other peroxidases, prosta-
glandin hydroperoxidase is part of a complex which
generates its own hydroperoxide substrate, prosta-
glandin G2. Type 3 reactions would occur with cer-
tain carcinogens which are metabolized by other
peroxidases and not PES. There is not a known
type 3 reaction at this time. This model suggests a
more expanded role for peroxidative activation of
carcinogens than previously conceptualized.
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Mechanisms by Which Renal
and Bladder Carcinogens are
Concentrated Within the
Urinary Tract
Target tissue metabolism is an important part of
our proposed model for explaining initiation of
chemical carcinogenesis in bladder and kidney.
Therefore, entry of these compounds into the kid-
ney and their concentration within the urinary tract
PES + A.A.
+ BENZIDINE
+ INDOMIETHIACIN
- BENZIDINE
-A.A.
t,4V
FIGURE 5. Radical formed at room temperature with 70 Mg of
solubilized prostaglandin hydroperoxidase, 500 WM
arachidonic acid and 200 JAM benzidine in 0.1 M phosphate
buffer pH 6.0. Measurements were performed over a 200 G
scan range in region around g = 2 with a modulation
amplitude of 1.0, a modulation frequency of 100 kHz and a
microwave power of 20 mW. The instrument was a Varian
E-109E EPR spectrometer.
is very important in the carcinogenic process. Or-
ganic acid and base transport by renal cortical slices
were investigated by using "3'I-hippuran and '4C-tet-
raethylammonium, respectively (Table 4). Since both
transport systems are energy dependent, their dra-
matic inhibition by anaerobic incubation conditions
suggests that they are valid model systems (29).
The 5-nitrofuran 3-hydroxymethyl-1-[(3-(5-nitro-2-
furyl-allydidene)amino]-hydantoin (HMN) inhibited
organic acid but not base transport. HMN inhibition
of organic acid transport was shown to be dose de-
pendent and reversible (not shown). This suggests
that the 5-nitro group of HMN functions as a car-
boxylate anion. Benzidine inhibited organic base but
not acid transport. These results are consistent
with transport of 5-nitrofurans and aromatic amines
by organic acid and base transport systems, respec-
tively, in the renal cortex. In addition to transport
by the organic ion systems, drugs and xenobiotics
are concentrated in urine by water reabsorption.
Under physiological conditions, greater than 98% of
the glomerular filtrate is removed from the lumen
of the renal tubule (water reabsorption). Therefore,
substrates which are not reabsorbed by the tubule
will reach high concentrations in the urinary space
(30). These specific transport and concentrating
properties of the kidney are further emphasized in
view of the fact that the kidney receives 20-25% of
the cardiac output at rest.
Table 4. Effect of HMN and benzidine on
organic acid and base transport.
Organic acid Organic base
Conditionsa (S:M)b (S:M)
95% N2:5% CO2 2.9 + 0.4a* 1.1 ± 0.1*
Control 10.4 + 1.2 12.3 ± 0.3
Diluent (0.13% DMSO) 11.7 + 1.2 12.1 ± 0.2
HMN (0.5mM) 4.9 ± 0.2* 13.1 ± 0.5
Benzidine (0.5mM) 9.8 ± 0.9 8.9 ± 0.4*
aControl represents transport of either ['3I]hippuran
(organic acid) or ['4C]tetraethylammonium (organic base) in
the absence of test agents. Unless otherwise indicated, slices
were incubated with a gas phase of 95% 02:5% CO2 (n = 3 or
more) (29).
bMean ± S.E.
*p < 0.01 compared to corresponding control value.
A FANFT Rat Feeding Study:
Evidence for Prostaglandin
Endoperoxide Synthetase
Involvement in the Initiation of the
Carcinogenic Process
The preceding results suggest that PES may be
involved in the initiation of certain chemical-induced
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[Type * 1 ROOH + Carcinogens
(ex. 5-nitrofurans)
(ex. aromatic amines)
Type #3 ROOH + Carcinogens
I (hypothetical) I
Inactivation
ROH +
+ Activated Carcinogen
covalent
binding to
nucleic acids
+
Initiation of
Chemical
carcinogenesis
ROOH = Prostaglandin G2, lipid peroxide, or H202
FIGURE 6. Proposed model for peroxidatic activation of carcinogens.
Table 5. Effect of aspirin on bladder lesions induced by 6 or 12 weeks of feeding FANFT.a
Rats with bladder lesionsb
Ropy Uniform Pleomorphic
No. of rats Hyperplasia microridges microvilli microvilli
Group Chemicals 6 wk 12 wk 6 wk 12 wk 6 wk 12 wk 6 wk 12 wk 6 wk 12 wk
1 0.2% FANFT 8 5 6 5 6 5 4 3 2 3
2 0.2% FANFT 8 6 2* 2** 2* 3 1*** 2 0 2
+ aspirin
3 0.1% FANFT 5 5 1 2 3 5 2 5 0 1
4 0.1% FANFT 5 6 0 0 2 Ot 1 Ot 0 0
+ aspirin
5 Aspirin 3 4c 0 0 0 0 0 0 0 0
6 Control 3 8c 0 0 0 0 0 0 0 0
aFrom Cohen et al. (31).
bHyperplasia was assessed by light microscopy, and the other lesions were assessed by scanning electron microscopy.
ctwo rats from each of groups 5 and 6 were killed 24 weeks after the beginning of the experiment; the other rats from these
groups were killed after 12 weeks.
*Group 1 versus group 2, p < 0.07.
**Group 1 versus group 2, p < 0.05.
***Group 1 versus group 2, p < 0.15.
tGroup 3 versus group 4, p < 0.025.
carcinogenic processes in kidney and bladder.
Therefore, if PES-catalyzed activation of carcino-
gens is prevented, initiation of the carcinogenic pro-
cess may be prevented. In a short-term study,
FANFT was fed to male 5-week-old Fischer rats as
0.2 or 0.1% of the diet with or without 0.5% aspirin
(31). Other rats were fed either aspirin in the diet or
a control diet without added chemicals. At the end
of 6 and 12 weeks of feeding, rats were killed from
each group and the bladder examined by light
microscopy and scanning electron microscopy. The
results, summarized in Table 5, demonstrate that
early preneoplastic lesions induced by FANFT are
inhibited by co-administration of aspirin.
A long-term experiment is in progress to deter-
mine if the bladder carcinomas induced by FANFT
are inhibited by aspirin administration. The rats
were fed FANFT and/or aspirin for 12 weeks and
then fed control diet until the end of the ex-
-periment. The rats fed 0.2% FANFT alone and
0.2% FANFT plus 0.5% aspirin have been killed (69
weeks after the start of the experiment). Gross
examination reveals bladder tumors in 18 of 21
(85%) rats fed FANFT and in 10 of 27 (37%) rats
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Initiation of Carcinogenic Effects
FIGURE 7. Model describing initial steps in 5-nitrofuran (5-NF)-induced bladder cancer.
fed FANFT plus aspirin (p < 0.004). In addition, nine
rats fed FANFT plus aspirin developed forestom-
ach tumors whereas none developed in rats fed
FANFT without aspirin. Of the rats with forestom-
ach tumors, only three also had a bladder tumor.
The microscopic evaluation of these tissues is in
progress.
Description of a Model System for
Initiation of 5-Nitrofuran-lnduced
Bladder Carcinogenesis
A scheme describing the initiation of 5-nitrofuran-
induced bladder carcinogenesis is shown in Figure
7. Target tissue metabolism is a salient feature of
this model. Bladder carcinogens are thought to
enter the kidney by facilitated transport and/or to
be concentrated by water reabsorption. The latter
may partially explain why these 5-nitrofurans cause
tumors in bladder but not liver. Carcinogens are ac-
tivated by the hydroperoxidase activity of PES to
electrophiles which covalently bind to macromole-
cules such as DNA. This results in the initiation of
the carcinogenic process. We have experimental evi-
dence to support each step in this model: (1) organic
acid transport of 5-nitrofurans (29); (2) prostaglandin
hydroperoxidase-catalyzed covalent binding of car-
cinogens to tissue macromolecules (14); and (3) pre-
vention of the expression of FANFT-induced lesions
by aspirin in rat feeding studies (31).
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